Andrée Rorive

1.3k total citations
49 papers, 344 citations indexed

About

Andrée Rorive is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Andrée Rorive has authored 49 papers receiving a total of 344 indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Oncology, 14 papers in Molecular Biology and 10 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Andrée Rorive's work include Cancer Treatment and Pharmacology (15 papers), Cutaneous Melanoma Detection and Management (7 papers) and Nonmelanoma Skin Cancer Studies (6 papers). Andrée Rorive is often cited by papers focused on Cancer Treatment and Pharmacology (15 papers), Cutaneous Melanoma Detection and Management (7 papers) and Nonmelanoma Skin Cancer Studies (6 papers). Andrée Rorive collaborates with scholars based in Belgium, Italy and Switzerland. Andrée Rorive's co-authors include Guy Jérusalem, Joëlle Collignon, Arjen Nikkels, Nadia Withofs, Roland Hustinx, Fabrice Giacomelli, Joël Aerts, Jorge E. Arrese, Frédéric Miévis and Nathalie Marchal and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.

In The Last Decade

Andrée Rorive

44 papers receiving 331 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Andrée Rorive Belgium 12 197 114 107 83 47 49 344
Carmelo Lupo Italy 11 176 0.9× 150 1.3× 137 1.3× 32 0.4× 32 0.7× 25 390
Davide Bosso Italy 12 132 0.7× 133 1.2× 167 1.6× 57 0.7× 25 0.5× 18 366
Yunyi Kong China 9 99 0.5× 111 1.0× 207 1.9× 32 0.4× 21 0.4× 14 330
L. Orgiano Italy 8 226 1.1× 180 1.6× 34 0.3× 18 0.2× 24 0.5× 13 382
Christian P. Turtschi Switzerland 4 200 1.0× 336 2.9× 166 1.6× 18 0.2× 61 1.3× 4 486
Akihisa Kiyota Japan 10 242 1.2× 161 1.4× 73 0.7× 17 0.2× 13 0.3× 11 357
Darab Kamanabrou Germany 6 372 1.9× 305 2.7× 81 0.8× 17 0.2× 32 0.7× 7 517
Amanda L. Treece United States 8 255 1.3× 195 1.7× 207 1.9× 56 0.7× 16 0.3× 14 444
Mazhar Ajaz United Kingdom 9 297 1.5× 147 1.3× 87 0.8× 37 0.4× 19 0.4× 12 424
Shuning Ding China 10 161 0.8× 190 1.7× 92 0.9× 24 0.3× 23 0.5× 19 381

Countries citing papers authored by Andrée Rorive

Since Specialization
Citations

This map shows the geographic impact of Andrée Rorive's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrée Rorive with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrée Rorive more than expected).

Fields of papers citing papers by Andrée Rorive

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrée Rorive. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrée Rorive. The network helps show where Andrée Rorive may publish in the future.

Co-authorship network of co-authors of Andrée Rorive

This figure shows the co-authorship network connecting the top 25 collaborators of Andrée Rorive. A scholar is included among the top collaborators of Andrée Rorive based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrée Rorive. Andrée Rorive is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Pottier, Charles, Dominique Baiwir, Gabriel Mazzucchelli, et al.. (2025). Targeting ferroptosis resistance resensitizes metastatic HR + HER2 − breast cancer cells to palbociclib‐hormone therapy. Cancer Communications. 45(4). 460–464. 1 indexed citations
2.
Rogiers, Anne, Laura McDonald, H Van Campenhout, et al.. (2023). Real-World Effectiveness, Safety, and Health-Related Quality of Life in Patients Receiving Adjuvant Nivolumab for Melanoma in Belgium and Luxembourg: Results of PRESERV MEL. Cancers. 15(19). 4823–4823. 8 indexed citations
3.
Somja, Joan, Patrick Collins, Andrée Rorive, et al.. (2021). The impact of COVID-19 on the new diagnoses of melanoma. European Journal of Dermatology. 31(4). 565–567. 13 indexed citations
4.
Marchal, Nathalie, et al.. (2021). Cemiplimab for locally advanced cutaneous squamous cell carcinoma: safety, efficacy, and position in therapy panel. Expert Review of Anticancer Therapy. 21(4). 355–363. 7 indexed citations
5.
Onesti, Concetta Elisa, Hélène Schroeder, Andrée Rorive, et al.. (2020). 1712P Risk of SARS-CoV-2 infection and outcome after infection: Experience from the day-care unit at CHU Liège in Belgium. Annals of Oncology. 31. S1007–S1007.
6.
Onesti, Concetta Elisa, Hélène Schroeder, Andrée Rorive, et al.. (2020). 1720P How do oncological patients perceive the COVID-19 pandemic? Experience from CHU Liège in Belgium. Annals of Oncology. 31. S1010–S1010. 1 indexed citations
7.
Rorive, Andrée, et al.. (2019). Granulomatous Reactions from Tattoos Following BRAF Inhibitor Therapy. Case Reports in Dermatology. 11(1). 101–107. 7 indexed citations
8.
Jérusalem, Guy, Andrée Rorive, & Joëlle Collignon. (2014). [The drug of the month: everolimus (Afinitor) for the treatment of metastatic breast cancer].. PubMed. 69(9). 510–7. 2 indexed citations
9.
Jérusalem, Guy, Andrée Rorive, & Joëlle Collignon. (2014). Use of mTOR inhibitors in the treatment of breast cancer: an evaluation of factors that influence patient outcomes. SHILAP Revista de lepidopterología. 8 indexed citations
10.
Nikkels‐Tassoudji, Nazli, et al.. (2014). Recurrent In Situ Melanoma Successfully Treated with Ingenol Mebutate. Dermatology and Therapy. 4(1). 131–135. 15 indexed citations
11.
Jérusalem, Guy, Andrée Rorive, & Joëlle Collignon. (2014). Use of mTOR inhibitors in the treatment of breast cancer: an evaluation of factors that influence patient outcomes. Breast Cancer Targets and Therapy. 6. 43–43. 32 indexed citations
12.
Arrese, J.E., et al.. (2012). Ipilimumab induces simultaneous regression of melanocytic naevi and melanoma metastases. Clinical and Experimental Dermatology. 38(3). 276–279. 13 indexed citations
13.
Paquet, Philippe, Andrée Rorive, Patrice Chiap, et al.. (2011). Pre-study and in-study validation of a SPE-LC–MS–MS method for the determination of 5-S-cysteinyldopa, a melanoma biomarker, in human plasma. Talanta. 84(2). 280–286. 4 indexed citations
14.
Withofs, Nadia, Andrée Rorive, Fabrice Giacomelli, et al.. (2010). 18F-fluoride PET/CT for assessing bone involvement in prostate and breast cancers. Nuclear Medicine Communications. 32(3). 168–176. 69 indexed citations
15.
Collignon, Joëlle, Christine Gennigens, Andrée Rorive, et al.. (2009). [Monoclonal antibodies and breast cancer. Current therapeutic progress].. PubMed. 64(5-6). 279–83. 1 indexed citations
16.
Gennigens, Christine, Joëlle Collignon, Guy Jérusalem, Andrée Rorive, & Brieuc Sautois. (2009). [Therapeutic monoclonal antibodies in hemato-oncology].. PubMed. 64(5-6). 264–7. 1 indexed citations
17.
18.
Quatresooz, Pascale, et al.. (2009). [Cutaneous adverse effects predicting the efficacy of targeted antineoplastic therapies].. PubMed. 64(5-6). 347–50. 3 indexed citations
19.
Pierard, Gérald, et al.. (2008). Le melanome cutane: innovations conceptuelles et therapeutiques, fruit de la recherche translationnelle.. RMLG. Revue médicale de Liège. 63(10). 1 indexed citations
20.
Jérusalem, Guy, et al.. (2006). Diagnostic and therapeutic management of carcinoma of unknown primary: radio-imaging investigations. Annals of Oncology. 17. x168–x176. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Carmelo Lupo Breakdown of academic impact, for papers by Davide Bosso Breakdown of academic impact, for papers by Yunyi Kong Breakdown of academic impact, for papers by L. Orgiano Breakdown of academic impact, for papers by Christian P. Turtschi Breakdown of academic impact, for papers by Akihisa Kiyota Breakdown of academic impact, for papers by Darab Kamanabrou Breakdown of academic impact, for papers by Amanda L. Treece Breakdown of academic impact, for papers by Mazhar Ajaz Breakdown of academic impact, for papers by Shuning Ding
Rankless by CCL
2026